Neogenomics, Inc. splits its revenue into 4 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Client Direct Billing at $135.6 million, 65% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
788
|
209
|
202
|
187
|
190
|
188
|
181
|
168
|
172
|
| Client Direct Billing |
538
+5.8%
share 68.4%
|
136
+2.5%
share 64.8%
|
138
+5.2%
share 68.4%
|
132
+7.8%
share 70.5%
|
133
+8.2%
share 70.1%
|
132
share 70.4%
|
131
share 72.3%
|
122
share 72.6%
|
123
share 71.7%
|
| Commercial Insurance |
143
+27.0%
share 18.2%
|
45
+37.5%
share 21.3%
|
36
+26.1%
share 18.0%
|
31
+24.5%
share 16.6%
|
31
+17.5%
share 16.5%
|
32
share 17.3%
|
29
share 15.9%
|
25
share 14.8%
|
27
share 15.5%
|
| Medicare And Other Governmental |
106
+21.6%
share 13.5%
|
29
+26.3%
share 13.9%
|
27
+28.2%
share 13.6%
|
24
+14.4%
share 12.9%
|
25
+16.8%
share 13.4%
|
23
share 12.2%
|
21
share 11.8%
|
21
share 12.6%
|
22
share 12.6%
|
| Self Pay Services |
—
|
—
|
—
|
-0
-143.6%
share -0.0%
|
-0
-106.2%
share -0.0%
|
0
share 0.0%
|
0
share 0.0%
|
0
share 0.0%
|
0
share 0.1%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Testing Laboratories (SIC 8734)
- Listed as
- NEO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Fort Myers, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1077183
- Former names
- AMERICAN COMMUNICATIONS ENTERPRISES INC (until Feb 5, 2002)
Other Services-Testing Laboratories companies
- UL Solutions Inc. ULS
- 20/20 Biolabs, Inc. AIDX
- Hypha Labs, Inc. FUNI
Source: SEC EDGAR filings. This is company-reported data, not investment advice.